Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1996 2
1997 1
1998 3
1999 5
2000 3
2001 1
2002 5
2003 2
2004 3
2005 6
2006 9
2007 8
2008 10
2009 12
2010 18
2011 9
2012 9
2013 11
2014 10
2015 5
2016 8
2017 6
2018 3
2019 2
2021 2
2022 4
2024 6
2025 5
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

143 results

Results by year

Filters applied: . Clear all
Page 1
Oral sildenafil versus bosentan for treatment of persistent pulmonary hypertension of the newborn: a randomized controlled trial.
Kallimath A, Deshpande S, Singh P, Garegrat R, Lakshminrusimha S, Maheshwari R, Suryawanshi P. Kallimath A, et al. BMC Pediatr. 2024 Nov 1;24(1):698. doi: 10.1186/s12887-024-05107-0. BMC Pediatr. 2024. PMID: 39487423 Free PMC article. Clinical Trial.
We aimed to compare oral sildenafil and bosentan as monotherapy in the treatment of neonates with PPHN. STUDY DESIGN: In this single-centre open-label randomized controlled trial (RCT), term and late preterm neonates with PPHN, defined as pulmonary arterial systolic pressu …
We aimed to compare oral sildenafil and bosentan as monotherapy in the treatment of neonates with PPHN. STUDY DESIGN: In this single- …
Tadalafil therapy for pulmonary arterial hypertension.
Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, Frumkin L, Barst RJ; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Galiè N, et al. Circulation. 2009 Jun 9;119(22):2894-903. doi: 10.1161/CIRCULATIONAHA.108.839274. Epub 2009 May 26. Circulation. 2009. PMID: 19470885 Clinical Trial.
METHODS AND RESULTS: In this 16-week, double-blind, placebo-controlled study, 405 patients with pulmonary arterial hypertension (idiopathic or associated), either treatment-naive or on background therapy with the endothelin receptor antagonist bosentan, were randomized to …
METHODS AND RESULTS: In this 16-week, double-blind, placebo-controlled study, 405 patients with pulmonary arterial hypertension (idiopathic …
Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W. McLaughlin VV, et al. J Am Coll Cardiol. 2010 May 4;55(18):1915-22. doi: 10.1016/j.jacc.2010.01.027. J Am Coll Cardiol. 2010. PMID: 20430262 Free article. Clinical Trial.
OBJECTIVES: This study assessed the efficacy and safety of inhaled treprostinil in pulmonary arterial hypertension (PAH) patients receiving therapy with either bosentan or sildenafil. BACKGROUND: There is no cure for PAH, despite effective treatments, and outcomes remain s …
OBJECTIVES: This study assessed the efficacy and safety of inhaled treprostinil in pulmonary arterial hypertension (PAH) patients receiving …
Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial.
Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, Søndergaard L. Iversen K, et al. Eur Heart J. 2010 May;31(9):1124-31. doi: 10.1093/eurheartj/ehq011. Epub 2010 Mar 3. Eur Heart J. 2010. PMID: 20202971 Clinical Trial.

Adding sildenafil to bosentan did not improve the 6 MWD significantly (21 vs. 8 m, P = 0.48), but increased saturation at rest (2.9 vs. -1.8%, P < 0.01). CONCLUSION: In Eisenmenger syndrome, treatment with bosentan significantly improved walking distance, pulmona

…
Adding sildenafil to bosentan did not improve the 6 MWD significantly (21 vs. 8 m, P = 0.48), but increased saturation at rest (2.9 v …
Bosentan and Pulmonary Hypertension Caused by COVID-19: A Pilot Randomized Double-blind Clinical Study.
Shokrollahi F, Pazoki A, Allami A, Aliakbari S, Ardali KR. Shokrollahi F, et al. Curr Vasc Pharmacol. 2024;22(6):437-446. doi: 10.2174/0115701611299843240607061547. Curr Vasc Pharmacol. 2024. PMID: 38874033 Clinical Trial.
An endothelin-1 (ET-1) receptor antagonist, such as bosentan, may be beneficial in treating elevated ET-1 levels. Hence, our study aimed to evaluate the therapeutic effects of bosentan in patients with COVID-19-induced PH. ...CONCLUSION: This study provided a mixed …
An endothelin-1 (ET-1) receptor antagonist, such as bosentan, may be beneficial in treating elevated ET-1 levels. Hence, our study ai …
Study on the comparison between Bosentan and Macitentan in the treatment of persistent pulmonary hypertension of the newborns, simultaneously on sildenafil: A randomized double-blinded non-inferiority parallel clinical trial.
Kashaki M, Mohazzab A, Radgoudarzi M, Bordbar A, Dabbagh S. Kashaki M, et al. Pediatr Neonatol. 2025 Jan;66(1):44-49. doi: 10.1016/j.pedneo.2023.12.007. Epub 2024 May 22. Pediatr Neonatol. 2025. PMID: 38797632 Free article. Clinical Trial.
No mortality case occurred. SPAP was reduced in both Bosentan and Macitenan groups with the mean difference in SPAP of 9 (95% CI: 7.34-10.65) in Bosentan and SPAP mean difference of 14 (95% CI: 12.12-15.86) in Macitentan group. ...Also, it is non-inferior to Bose …
No mortality case occurred. SPAP was reduced in both Bosentan and Macitenan groups with the mean difference in SPAP of 9 (95% CI: 7.3 …
BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.
King TE Jr, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, Valeyre D, Leconte I, Morganti A, Roux S, Behr J. King TE Jr, et al. Am J Respir Crit Care Med. 2011 Jul 1;184(1):92-9. doi: 10.1164/rccm.201011-1874OC. Epub 2011 Apr 7. Am J Respir Crit Care Med. 2011. PMID: 21474646 Clinical Trial.
The safety profile for bosentan was similar to that observed in other trials. CONCLUSIONS: The primary objective in the Bosentan Use in Interstitial Lung Disease-3 trial was not met. Bosentan was well tolerated. Clinical trial registered with www.clinicaltria …
The safety profile for bosentan was similar to that observed in other trials. CONCLUSIONS: The primary objective in the Bosentan …
BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.
King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, Stähler G, Leconte I, Roux S, Raghu G. King TE Jr, et al. Am J Respir Crit Care Med. 2008 Jan 1;177(1):75-81. doi: 10.1164/rccm.200705-732OC. Epub 2007 Sep 27. Am J Respir Crit Care Med. 2008. PMID: 17901413 Clinical Trial.
MEASUREMENTS AND MAIN RESULTS: A total of 158 patients randomly received bosentan (n = 74) or placebo (n = 84). Bosentan showed no superiority over placebo in six-minute-walk distance (6MWD) up to Month 12, the primary efficacy endpoint. ...Changes from baseline up …
MEASUREMENTS AND MAIN RESULTS: A total of 158 patients randomly received bosentan (n = 74) or placebo (n = 84). Bosentan showe …
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis.
Seibold JR, Denton CP, Furst DE, Guillevin L, Rubin LJ, Wells A, Matucci Cerinic M, Riemekasten G, Emery P, Chadha-Boreham H, Charef P, Roux S, Black CM. Seibold JR, et al. Arthritis Rheum. 2010 Jul;62(7):2101-8. doi: 10.1002/art.27466. Arthritis Rheum. 2010. PMID: 20506355 Clinical Trial.
We tested this hypothesis in a 12-month trial of bosentan, a nonselective endothelin receptor antagonist, as a therapy for SSc-related interstitial lung disease (ILD). ...Secondary end points included time to death or worsening results of pulmonary function tests (PFTs). T …
We tested this hypothesis in a 12-month trial of bosentan, a nonselective endothelin receptor antagonist, as a therapy for SSc-relate …
Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial.
Baughman RP, Culver DA, Cordova FC, Padilla M, Gibson KF, Lower EE, Engel PJ. Baughman RP, et al. Chest. 2014 Apr;145(4):810-817. doi: 10.1378/chest.13-1766. Chest. 2014. PMID: 24177203 Clinical Trial.
The objective of this study was to determine the effect of bosentan therapy on pulmonary arterial hemodynamics in patients with SAPH. METHODS: This 16-week study was a double-blind, placebo-controlled trial of either bosentan or placebo in patients with SAPH confirm …
The objective of this study was to determine the effect of bosentan therapy on pulmonary arterial hemodynamics in patients with SAPH. …
143 results